scorecardresearch
Add as a preferred source on Google
Monday, December 1, 2025
TopicCorbevax

Topic: Corbevax

DCGI approval in, but here’s why you can’t choose Corbevax as your booster just yet

Corbevax was, over the weekend, approved for heterologous use as a Covid booster shot by apex drug regulator Drugs Controller General of India.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

Cleared Corbevax for ages 12-14 based on interim safety & immune response data, govt tells LS

Govt was responding to question on availability of safety & efficacy data for Corbevax, and whether it had been peer-reviewed. It sidestepped queries on efficacy & peer-review.

Corbevax is India’s ‘lowest priced vaccine’, saves exchequer Rs 1500 cr, Biological E says

Hyderabad-based Biological E has priced its vaccine at Rs 990 in the private market. For the government, however, the vaccine is at just Rs 145, making it very affordable.

DCGI gives emergency use approval to Biological E’s Corbevax vaccine for kids aged 12-18

It is the second Covid vaccine to get approval for use in children in India after Bharat Biotech's Covaxin.

Govt panel recommends Biological E’s Corbevax for emergency use among 12 to 18-year-olds

The recommendation has been sent to Drug Controller General of India for final approval. DCGI had earlier approved Corbevax for restricted use in emergency situations for adults.

5 months after nod, ZyCov-D set for rollout in 7 states. Bihar starts getting 1st set of shots

It will be used in six other states too. Corbevax of Biological E is also expected to start coming in this month. No decision so far on the government procuring Covovax.

Corbevax, a new patent-free Covid vaccine, is an important step to end pandemic

Corbevax was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine.

What it will take to vaccinate the world against Covid

A Q&A with vaccine scientist Peter Hotez, author of 'Preventing the Next Pandemic', on developing a low-cost Covid vaccine, and why Omicron won’t be the end of the pandemic.

Corbevax maker says ‘too much dependence on MNCs, focus on new tech’ behind vaccine inequity

Corbevax co-developer Dr Peter Hotez says the vaccine will 'make up for lost time' in race to immunise millions and its patent was waived in the spirit of 'decolonisation'.

On Camera

There’s pollution, violence, volcanic ash on my screen. And yet an email is more stressful

Years are quietly being stripped off my lifespan, and somehow that doesn’t ruin my day. But getting scolded for one careless word in an email? That can send me spiralling.

Karnataka startups feel the chill as global funding winter sets in. Fintech emerges as sole bright spot

The state raises just $2.7 billion in first nine months of 2025 compared to $4.5 billion last year, with late-stage investments hit hardest.

What’s expected from Putin’s India visit in December—Defence Secretary explains

ThePrint had previously reported that India & Russia are talking about 5 more regiments of the S-400, but no contracts are to be signed during the Russian president's visit.

Gaali cricket: Bavuma stands tall, India’s Test ego cut to size

The India-South Africa series-defining fact is the catastrophic decline of Indian red ball cricket where a visiting team can mock us with the 'grovel' word.